Oncopeptides AB (publ)
ONPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.07 | 0.03 | 0.04 |
| FCF Yield | -58.25% | -51.20% | -58.09% | -116.69% |
| EV / EBITDA | -1.38 | -2.15 | -1.23 | -0.68 |
| Quality | ||||
| ROIC | -147.22% | -131.37% | -114.39% | -635.28% |
| Gross Margin | 91.59% | 103.06% | 99.93% | 55.09% |
| Cash Conversion Ratio | 0.92 | 1.10 | 1.20 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 55.88% | -33.23% | – | – |
| Free Cash Flow Growth | 6.81% | 33.90% | 72.11% | -15.46% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 0.20 | 1.05 | 0.25 |
| Interest Coverage | -22.40 | -43.81 | -395.64 | -1,498.86 |
| Efficiency | ||||
| Inventory Turnover | 0.61 | -0.44 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,763.01 | 4,285.02 | -1,716,626.39 | -208.68 |